HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
A. Llombart-Cussac,J. Cortés,13 Authors,A. Prat
2017 · DOI: 10.1016/S1470-2045(17)30021-9
The Lancet Oncology · 255 Citations
TLDR
The primary outcome was the ability of the HER2-enriched subtype to predict pathological complete response at the time of surgery and safety was assessed in all patients who received at least one part of study treatment.
Cited Papers
Citing Papers